Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 3, 2026

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
14:22

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

Plerixafor for autologous CD34 cell mobilization.

Huda Salman1, Hillard M Lazarus

  • 1Division of Hematology-Oncology, Blood and Marrow Transplant Program, University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Core Evidence
|April 7, 2011
PubMed
Summary

Plerixafor, combined with G-CSF, significantly improves hematopoietic stem cell mobilization for cancer patients. This safe approach yields more CD34(+) cells compared to G-CSF alone, enhancing treatment options.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Blood neoplasia·2026
Same author

FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AML.

NPJ precision oncology·2026
Same author

Molecular Expression Differences in Specific Blood Mononuclear Cell-Types Identify Patients With AL Amyloidosis.

Journal of cellular and molecular medicine·2025
Same author

Endogenous and exogenous cytokines: An overview and introduction.

Best practice & research. Clinical haematology·2025
Same author

Cytokines in hematology, hematopoietic cell transplantation and immune effector cell therapy: Preface.

Best practice & research. Clinical haematology·2025
Same author

Signalling Network Analysis of Blood Mononuclear Cells From Clinical Samples by Bivariate Correlation.

Journal of cellular and molecular medicine·2025

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • High-dose chemotherapy with autologous hematopoietic cell transplantation is vital for hematologic malignancies.
  • Existing mobilization strategies frequently fail to yield sufficient CD34(+) cells.
  • The CXCR4/SDF-1 axis is critical for hematopoietic progenitor cell homing and mobilization.

Purpose of the Study:

  • To evaluate the efficacy of plerixafor in enhancing hematopoietic stem cell mobilization.
  • To assess the safety profile of plerixafor when combined with G-CSF.
  • To compare the number of mobilized CD34(+) cells using plerixafor plus G-CSF versus G-CSF alone.

Main Methods:

  • Phase II and III clinical trials were conducted.
  • Plerixafor, a CXCR4 antagonist, was administered in conjunction with granulocyte colony-stimulating factor (G-CSF).
Keywords:
CD34autologous hematopoietic cell transplantgranulocyte colony-stimulating factor (G-CSF)lymphomamyelomaplerixafor

More Related Videos

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
10:42

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid

Published on: April 11, 2019

Related Experiment Videos

Last Updated: Jun 3, 2026

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
14:22

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

Published on: July 16, 2011

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
10:42

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid

Published on: April 11, 2019

  • Mobilization of CD34(+) cells was assessed.

    • Main Results:

    • The combination of plerixafor and G-CSF significantly improved CD34(+) cell mobilization compared to G-CSF alone.
    • The treatment regimen demonstrated a favorable safety profile with minimal adverse events.
    • Greater quantities of CD34(+) cells were collected, potentially improving transplant outcomes.

    Conclusions:

    • Plerixafor in combination with G-CSF is an effective and safe method for enhancing hematopoietic stem cell mobilization.
    • This strategy offers a significant advantage over G-CSF alone for patients undergoing autologous transplantation.
    • Future applications of plerixafor are being explored for allogeneic transplants and other diseases.